928385-53-9Relevant academic research and scientific papers
1,5-Benzodiazepine inhibitors of HCV NS5B polymerase
McGowan, David,Nyanguile, Origene,Cummings, Maxwell D.,Vendeville, Sandrine,Vandyck, Koen,Van den Broeck, Walter,Boutton, Carlo W.,De Bondt, Hendrik,Quirynen, Ludo,Amssoms, Katie,Bonfanti, Jean-Francois,Last, Stefaan,Rombauts, Klara,Tahri, Abdellah,Hu, Lili,Delouvroy, Frederic,Vermeiren, Katrien,Vandercruyssen, Genevieve,Van der Helm, Liesbet,Cleiren, Erna,Mostmans, Wendy,Lory, Pedro,Pille, Geert,Van Emelen, Kristof,Fanning, Gregory,Pauwels, Frederik,Lin, Tse-I,Simmen, Kenneth,Raboisson, Pierre
scheme or table, p. 2492 - 2496 (2009/12/07)
Optimization through parallel synthesis of a novel series of hepatitis C virus (HCV) NS5B polymerase inhibitors led to the identification of (R)-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(6-methylpyridine-2-carbonyl)-2,3,4,5,10,11-hexahydr
BENZODIAZEPINES AS HCV INHIBITORS
-
Page/Page column 79, (2008/06/13)
The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates Io benzodiazepine compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
